Regeneron Pharmaceuticals (NASDAQ:REGN) Upgraded at Wall Street Zen

Key Points

• Wall Street Zen upgraded Regeneron from a "hold" to a "buy" and the stock carries a MarketBeat consensus of "Moderate Buy" with a $826.59 price target, though analysts are split — JPMorgan raised its target to $950 while several banks trimmed theirs modestly.
• Strong Q1 results: Regeneron reported revenue up ~19% and EPS of $9.47 (beating $8.91 estimates) and announced a $3 billion share buyback, but shares fell as investors flagged a 10% year‑over‑year drop in net income and mixed forward expectations.
• Insiders sold 3,774 shares (~$2.94M) in the past 90 days (insiders own 7.02%, institutions 83.31%); the stock opened at $701.42, with a market cap of $74.15B and a P/E of 17.09.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) was upgraded by investment analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a report issued on Saturday.

REGN has been the subject of several other reports. Barclays cut their target price on shares of Regeneron Pharmaceuticals from $923.00 to $917.00 and set an "overweight" rating for the company in a research report on Thursday. Wells Fargo & Company cut their target price on shares of Regeneron Pharmaceuticals from $825.00 to $800.00 and set an "equal weight" rating for the company in a research report on Thursday. Royal Bank Of Canada cut their target price on shares of Regeneron Pharmaceuticals from $779.00 to $762.00 and set a "sector perform" rating for the company in a research report on Thursday. JPMorgan Chase & Co. upped their target price on shares of Regeneron Pharmaceuticals from $850.00 to $950.00 and gave the stock an "overweight" rating in a research report on Monday, February 2nd. Finally, Truist Financial cut their target price on shares of Regeneron Pharmaceuticals from $801.00 to $796.00 and set a "buy" rating for the company in a research report on Thursday. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and eight have assigned a Hold rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $826.59.

Regeneron Pharmaceuticals Stock Down 0.8%

REGN opened at $701.42 on Friday. The company has a fifty day moving average price of $756.81 and a 200-day moving average price of $735.17. The firm has a market capitalization of $74.15 billion, a P/E ratio of 17.09, a price-to-earnings-growth ratio of 1.63 and a beta of 0.30. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.57 and a quick ratio of 3.39. Regeneron Pharmaceuticals has a one year low of $476.49 and a one year high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 EPS for the quarter, beating analysts' consensus estimates of $8.91 by $0.56. The firm had revenue of $3.61 billion during the quarter, compared to analyst estimates of $3.48 billion. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. The business's revenue for the quarter was up 19.0% on a year-over-year basis. During the same period in the previous year, the business earned $8.22 EPS. Equities research analysts expect that Regeneron Pharmaceuticals will post 35.98 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Arthur F. Ryan sold 100 shares of the firm's stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $778.53, for a total value of $77,853.00. Following the sale, the director directly owned 17,803 shares of the company's stock, valued at $13,860,169.59. This trade represents a 0.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Huda Y. Zoghbi sold 1,638 shares of the firm's stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $781.33, for a total value of $1,279,818.54. Following the completion of the sale, the director directly owned 1,703 shares in the company, valued at $1,330,604.99. The trade was a 49.03% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 3,774 shares of company stock valued at $2,942,738 over the last ninety days. 7.02% of the stock is owned by insiders.

Institutional Trading of Regeneron Pharmaceuticals

Several large investors have recently modified their holdings of the business. Insigneo Advisory Services LLC grew its stake in shares of Regeneron Pharmaceuticals by 3.0% in the fourth quarter. Insigneo Advisory Services LLC now owns 445 shares of the biopharmaceutical company's stock worth $343,000 after purchasing an additional 13 shares during the last quarter. Guardian Wealth Advisors LLC NC raised its stake in Regeneron Pharmaceuticals by 3.3% in the fourth quarter. Guardian Wealth Advisors LLC NC now owns 443 shares of the biopharmaceutical company's stock worth $342,000 after buying an additional 14 shares in the last quarter. TD Private Client Wealth LLC raised its stake in Regeneron Pharmaceuticals by 9.7% in the fourth quarter. TD Private Client Wealth LLC now owns 169 shares of the biopharmaceutical company's stock worth $130,000 after buying an additional 15 shares in the last quarter. MCF Advisors LLC raised its stake in Regeneron Pharmaceuticals by 50.0% in the fourth quarter. MCF Advisors LLC now owns 45 shares of the biopharmaceutical company's stock worth $35,000 after buying an additional 15 shares in the last quarter. Finally, Boyd Watterson Asset Management LLC OH raised its stake in Regeneron Pharmaceuticals by 1.4% in the first quarter. Boyd Watterson Asset Management LLC OH now owns 1,087 shares of the biopharmaceutical company's stock worth $840,000 after buying an additional 15 shares in the last quarter. 83.31% of the stock is owned by institutional investors.

Key Stories Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Regeneron reported a stronger-than-expected Q1 (revenue up ~19%, EPS beat) and announced a $3 billion share buyback — fundamentals and the buyback are clear upside catalysts for shareholder value. Regeneron reports strong Q1 CY2026
• Positive Sentiment: Guggenheim raised its price target to $995 and retained a Buy — that implies sizable upside and supports sentiment among growth/value investors. Guggenheim raises REGN target to $995
• Neutral Sentiment: Zacks highlights REGN as a long-term value pick — supportive narrative for buy-and-hold investors but not an immediate price catalyst. Why Regeneron is a Top Value Stock
• Neutral Sentiment: Several banks trimmed price targets modestly (Barclays, Truist, Wells Fargo) but largely kept positive/market-weight ratings — suggests analysts revised models after Q1 details but remain constructive overall. Analyst PT changes after Q1
• Negative Sentiment: Royal Bank of Canada cut its target to $762 and moved to a "sector perform" stance — a more cautious view that likely weighed on intraday selling pressure. RBC lowers REGN target to $762
• Negative Sentiment: Coverage and model cuts followed the Q1 release despite the beat; investors focused on items such as a 10% drop in net income year-over-year (even as revenue rose), which may have trimmed near-term expectations. Regeneron Q1 2026 net income falls 10%
• Negative Sentiment: Market reaction: shares fell despite the beat — coverage (Seeking Alpha) points to investor disappointment or guidance/forward assumptions as the reason for the drop. That momentum explains today's weaker price action. Regeneron drops despite Q1 beat

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc NASDAQ: REGN is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.